Research Grade Ianalumab (DHJ42201)

Catalog No.

DHJ42201

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

BR3, TNFRSF13C, BAFF receptor, BLyS receptor 3, Tumor necrosis factor receptor superfamily member 13C, CD268, B-cell-activating factor receptor, BAFFR, BAFF-R

Concentration

1.1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q96RJ3

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

VAY-736, CAS: 1929549-92-7

Clone ID

Ianalumab

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity, PMID: 30826774

Sjögren's syndrome: Old and new therapeutic targets, PMID: 31831255

Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound, PMID: 33095139

Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome, PMID: 32067925

Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis, PMID: 33002950

[Sjögren's syndrome: from diagnosis to treatment], PMID: 33689243

Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia, PMID: 31138521

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib, PMID: 30737226

Document Download

Research Grade Ianalumab.pdf